Spinal Muscular Atrophy (SMA) represents a group of genetic neuromuscular disorders characterized by the progressive degeneration of anterior horn cells in the spinal cord
The primary clinical hallmark of SMA is progressive, symmetric weakness and muscle atrophy, primarily affecting proximal limb groups more than distal ones, without upper motor neuron signs
Type I (Werdnig-Hoffmann Disease): The most severe acute infantile form, manifesting before 6 months of age
. Affected infants exhibit severe hypotonia, poor sucking and swallowing abilities, and early respiratory compromise . These infants never achieve independent sitting and typically have a life expectancy of less than two years without advanced intervention . Type II (Intermediate / Chronic Infantile): Onset occurs between 6 and 18 months
. Children achieve independent sitting but cannot stand or walk without assistance . Lifespan ranges from early childhood to the third decade . Type III (Kugelberg-Welander Disease): Chronic juvenile SMA presenting after 18 months of age
. Individuals learn to walk independently, though they may gradually lose this ability later in life . Normal life expectancy is often preserved . Type IV (Adult-Onset): A mild form developing in adulthood, featuring gradual proximal muscle weakness and a normal life expectancy
.
Recognizing these distinctions helps clinicians establish early supportive management, involving multidisciplinary care to address motor, orthopedic, and respiratory needs